Tesamorelin: GHRH, Growth Hormone & IGF-1

Hypothalamic GHRH physiology

Growth hormone-releasing factor — GHRH, GHRF, or GRF — is a hypothalamic peptide. It acts on the anterior pituitary to request synthesis and pulsatile release of growth hormone. Tesamorelin is described as a synthetic analogue of that signal, not as exogenous growth hormone.^1,2

That distinction matters. A GHRH analogue asks the pituitary to release endogenous GH. That is not the same as giving GH. It is also not the same as a shorter GRF fragment or another secretagogue with a different receptor. What Is Tesamorelin? fixes the 44-amino-acid identity and the hexenoyl modification.

This page explains the axis. It is not a use guide, it does not translate biomarkers into an aesthetic result, and it does not apply EGRIFTA labeling to Peptra research material. The broader context is in the tesamorelin hub.

The pituitary somatotroph

Somatotrophs are the pituitary cells that make and secrete GH. FDA labeling states that, in vitro, tesamorelin binds and stimulates human GRF receptors with similar potency to endogenous GRF.¹

That receptor statement is pharmacology of the active moiety in the studied context. It does not say that every preparation labeled tesamorelin reproduces the same exposure, potency, or immunologic profile. The licensed product’s formulation, salt, and excipients belong to that product.

Growth-hormone secretion

GHRH stimulates synthesis and pulsatile release of GH. GH has anabolic and lipolytic effects described in the label: it interacts with receptors on several cell types, including chondrocytes, osteoblasts, myocytes, hepatocytes, and adipocytes.¹

“Lipolytic” in that paragraph is general GH pharmacology language. It is not, by itself, proof of body-weight loss, subcutaneous-fat reduction, or a result in people without HIV. The trials that measured visceral fat in people with HIV are on another page. Clinical trials of visceral fat in people with HIV

Downstream IGF-1 signaling

Some, but not all, GH effects are mediated by IGF-1 produced in the liver and in peripheral tissues. Labeling states that tesamorelin stimulates growth-hormone secretion and subsequently increases IGF-1 and IGFBP-3 levels.¹

The Phase 3 trials also recorded IGF-1 increases in the investigational setting. An IGF-1 rise is an axis biomarker. Labeling warns that the effects of prolonged IGF-1 elevations are unknown and describes IGF-1 monitoring as part of the approved product’s precautions.^1,3,4,5

In the same pharmacodynamic summary, labeling states that no clinically significant changes in other pituitary hormones — TSH, LH, ACTH, and prolactin — were observed in EGRIFTA trials. That describes the studied, labeled product, not a different research material.¹

Tesamorelin receptor activity

The described activity is GRF-receptor agonism on the somatotroph. The immediate result the label emphasizes is GH secretion and a later IGF-1 increase. The body-composition result the pivotal trials measured was not “the axis in the abstract”: it was visceral adipose tissue in adults with HIV and lipodystrophy or abdominal fat accumulation.^1,3,4

Moving a biomarker and moving an imaging-measured fat compartment are different facts. Moving scale weight is a third fact. Labeling states that EGRIFTA is not indicated for weight-loss management.¹ Visceral fat is not the same as body weight

What a GH or IGF-1 change does not prove

• It does not, by itself, prove fat loss in every population.
• It does not prove muscle gain.
• It does not prove an anti-aging effect.
• It does not prove an athletic benefit or clinical superiority over another approach.
• It does not turn Peptra research material into the product whose pharmacodynamics the label describes.

Labeling also groups precautions tied to this axis for the approved product: neoplasm risk, elevated IGF-1, fluid retention, glucose intolerance or diabetes, and hypersensitivity. Those categories are summarized on the regulatory page without becoming a treatment guide.¹ EGRIFTA, FDA & WADA

Formulation context still matters

Active-moiety pharmacology does not make two products interchangeable. Labeling states that EGRIFTA WR and EGRIFTA SV are not substitutable even though they share tesamorelin as the active ingredient. A research vial sits even farther from that studied, licensed product context.¹

This page does not reproduce preparation or administration instructions. Mechanism is cited so that trials and labeling can be read, not so that a use can be directed.